Enoxaparin Use in Patients with Elevated Liver Enzymes

Introduction to Enoxaparin Therapy

The American Urological Association guidelines specify that enoxaparin should be used with extreme caution in patients with liver failure and elevated INR (≥1.5), not simply elevated transaminases alone 1
Elevations of serum aminotransferases are recognized adverse reactions to enoxaparin therapy, not contraindications to its use 1

Enoxaparin may be administered with close monitoring for bleeding complications in patients with elevated transaminases alone 1
The critical distinction is between elevated transaminases (which represent hepatocellular injury) versus impaired hepatic synthetic function (reflected by elevated INR), which affects coagulation factor production 1

Exercise extreme caution and consider alternative anticoagulation strategies when liver failure with INR ≥1.5 is present 1
Unfractionated heparin may be preferred as it allows more precise titration and monitoring via aPTT in patients with liver failure 2

For patients <75 years: 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours, according to the American Heart Association guidelines 4, 5
For patients ≥75 years: 0.75 mg/kg subcutaneously every 12 hours without initial IV bolus, as recommended by the American Heart Association 4, 5
For creatinine clearance <30 mL/min: reduce to 1 mg/kg subcutaneously once daily, as suggested by the National Comprehensive Cancer Network 3, 4, 5, 6

Baseline and serial complete blood counts to detect thrombocytopenia are essential, according to the American Urological Association guidelines 1
Serial hepatic function tests (ALT, AST, bilirubin, INR, albumin) to distinguish hepatocellular injury from synthetic dysfunction should be performed, as recommended by the American Urological Association 1

Unfractionated heparin allows precise titration via aPTT monitoring and has a shorter half-life, making it a suitable alternative in patients with severe hepatic dysfunction, according to the American Heart Association 2
Fondaparinux may be considered but requires dose adjustment for renal impairment (contraindicated if CrCl <30 mL/min), as suggested by the National Comprehensive Cancer Network 2, 7
Bivalirudin offers advantages in patients with combined renal insufficiency and bleeding risk, according to the American Heart Association 2, 6